Open AccessChimeric Antigen Receptor T Cells for Multiple Myeloma
Author(s) -
Andrew J. Cowan,
Sherilyn A. Tuazon,
Andrew J. Portuguese,
Damian J. Green
Publication year - 2021
Publication title -
the cancer journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.825
H-Index - 89
eISSN - 1540-336X
pISSN - 1528-9117
DOI - 10.1097/ppo.0000000000000506
Subject(s) - chimeric antigen receptor , multiple myeloma , medicine , antigen , cd38 , immunology , monoclonal antibody , autologous stem cell transplantation , cell therapy , cancer research , antibody , immunotherapy , immune system , oncology , stem cell , biology , cd34 , genetics
Despite improvements in effective therapy, multiple myeloma remains incurable, and virtually all patients will face relapsed disease at some point after diagnosis. The prognosis for relapsed myeloma after developing resistance to anti-CD38 monoclonal antibodies, proteasome inhibitors, immunomodulatory agents, and autologous stem cell transplantation has been poor; however, the development of immune effector cell therapy with chimeric antigen receptor (CAR) T cells may dramatically improve the outlook for patients, although none of these therapies are approved for MM to date. Herein, we review the development and history of CAR T-cell therapy for multiple myeloma, mechanisms of resistance, and strategies to improve outcomes with CAR T therapy.